ClinicalTrials.gg
CompletedNCT02967211REGAIN CONTROLUpdated Apr 25, 2022

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulin in Patients Already Using Basal Insulin

A Phase 4 interventional study of insulin glargine (U300) and insulin glargine (U100) in Diabetes Mellitus, Type 2, sponsored by Sanofi. Completed at 118 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-25.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
609
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.

Enrollment
29th of 175
609 · median 253
Started
2015
with 13 others
Phase 4
103 of 176
2 open now
Registered
138th of 176
by date
Lead sponsor
82 of 176
Sanofi

Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 29th largest by enrollment of the 175 interventional ones that give a count, is one of 14 that started in 2015, is one of 103 in phase 4, and was the 138th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Primary Objective:

To demonstrate noninferiority of Toujeo versus "standard of care" basal insulin therapy as measured by glycated hemoglobin (HbA1c) change

Secondary Objectives:

  • To demonstrate superiority of Toujeo versus "standard of care" basal insulin if non-inferiority criterion is met, measured by HbA1c change.
  • To compare Toujeo to other "standard of care" basal insulin in terms of patient persistence with assigned basal insulin therapy with or without intensification.
  • Risk of hypoglycemia including documented, symptomatic hypoglycemia (≤70 mg/dL) or severe (according to ADA Working Group).
  • Change in fasting plasma glucose (FPG).
  • Change in body weight.
  • Differences in patient reported outcomes measured by Diabetes Treatment Satisfaction Questionnaire Status and Change versions (DTSQs and DTSQc).
  • Change in hypoglycemic control subscale (HCS).
  • Healthcare resource utilization including hospitalizations and emergency department or other health care provider visits and healthcare costs.
Read the detailed description

The total study duration will be up to 55 weeks, consisting of a 1 week screening period at the site, a 26 week treatment period, and a 26 week extension period.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with type 2 diabetes insufficiently controlled ( >7%) with current (≥6 months) "standard of care" basal insulin therapy (including insulin glargine U100, Levemir, NPH, or Tresiba) with or without oral agents (metformin, sulfonylurea, thiazolidinedione, DPP-4 inhibitor, SGLT-2 inhibitor, glinides, α glucosidase inhibitors) and with or without use of a GLP-1 receptor agonist.
  • Fasting plasma glucose (FPG) >130 mg/dL (7.2 mmol/L).
  • Adult patients who have signed Form (ICF) and privacy form(s).

Exclusion criteria

Exclusion criteria:

  • ≤7%, no upper bound.
  • Age \<18 years.
  • Type 1 diabetes mellitus.
  • Any abnormality identified on physical examination, laboratory tests, or vital signs at the time of screening, or any major systemic disease resulting in short that in the opinion of the Investigator would restrict or limit the patient's successful participation for the duration of the study.
  • Use of any product containing short or rapid acting insulin since the time of diagnosis with type 2 diabetes mellitus other than temporary use during a pregnancy or hospitalization.
  • Use of any product containing short or rapid acting insulin occurring within 3 months prior to the time of screening.
  • Use of oral hypoglycemic agents other than those noted in the inclusion criteria, GLP-1 receptor agonists not approved for use with insulin, or any agent (drug, biologic, device) within 3 months prior to the time of screening.
  • All to "standard of care" insulin therapy or warnings/precautions of use as displayed in the respective National Product labeling for these products.
  • to insulin glargine or Toujeo .
  • Pregnancy or lactation.
  • Women of with no effective method.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
609 participants (actual)

Study arms

  • Experimental
    Toujeo

    Toujeo will be administered once daily in addition to non-insulin antidiabetic agents

    Drug: insulin glargine (U300)

  • Active comparator
    "Standard of care" commercially available basal insulin

    Lantus, Humulin Neutral Protamine Hagedorn (NPH), Levemir, and Tresiba or other basal insulin, including biosimilar insulin will be administered once or twice daily according to label in addition to non-insulin antidiabetic agents

    Drug: insulin glargine (U100) · Drug: NPH insulin · Drug: insulin detemir · Drug: insulin degludec

Interventions

  • Pharmaceutical form: solution Route of administration: subcutaneous

    Also known as: HOE901; Toujeo

  • Pharmaceutical form: solution Route of administration: subcutaneous

    Also known as: HOE901; Lantus

  • Pharmaceutical form: solution Route of administration: subcutaneous

    Also known as: Humulin NPH

  • Pharmaceutical form: solution Route of administration: subcutaneous

    Also known as: Levemir

  • Pharmaceutical form: solution Route of administration: subcutaneous

    Also known as: Tresiba

06

What researchers measure

Primary outcomes

  1. Change in HbA1c (percentage %)

    Time frame: Baseline to 6 months

Secondary outcomes

  1. Proportion of patients who remain on assigned basal insulin therapy before intensification (persistent with assigned therapy)

    Time frame: At Month 6 and Month 12

  2. Proportion of patients who remain on assigned basal insulin therapy whether intensification occurred or not

    Time frame: At Month 6 and Month 12

  3. Proportion of patients who achieve target HbA1c (<6.5%, <7%, <7.5%, <8.0%)

    Time frame: At Month 6 and Month 12

  4. Proportion of patients with HbA1c target (thresholds listed above) (attainment of metabolic benefit) without documented (blood glucose (BG) ≤70 mg/dl [3.9 mmol/L]) symptomatic or severe

    Time frame: At Month 6 and Month 12

  5. Proportion of patients with HbA1c target (thresholds listed above) (attainment of metabolic benefit) without documented (BG <54 mg/dL, [3.0 mmol/L]) symptomatic or severe hypoglycemia

    Time frame: At Month 6 and Month 12

  6. Change in HbA1c (percentage %)

    Time frame: Baseline, Month 12

  7. Percentage of patients whose HbA1c decreased at least 0.5%

    Time frame: At Month 6 and Month 12

  8. Percentage of patients whose HbA1c decreased at least 0.5%

    Time frame: At Month 6 and maintained at Month 12

  9. Percentage of patients requiring intensification

    Time frame: At Month 6 and Month 12

  10. Time to intensification

    Time frame: At Month 6 and Month 12

  11. Change in fasting plasma glucose

    Time frame: From baseline to Month 6 and Month 12

07

Study locations

118 sites
  • Investigational Site Number 076-001
    Curitiba, 80810-140, Brazil
  • Investigational Site Number 076008
    Fortaleza, 60115-282, Brazil
  • Investigational Site Number 076004
    Fortaleza, Brazil
  • Investigational Site Number 076009
    Rio de Janeiro, 202110340, Brazil
  • Investigational Site Number 076-003
    Sao Paulo, 01244-030, Brazil
  • Investigational Site Number 076011
    São José dos Campos, 12243-280, Brazil
  • Investigational Site Number 076006
    São paulo, 01223-001, Brazil
  • Investigational Site Number 076005
    São Paulo, 04024-002, Brazil
  • Investigational Site Number 076010
    Taguatinga, 72155000, Brazil
  • Investigational Site Number 246008
    Helsinki, 00100, Finland
  • Investigational Site Number 246007
    Muurame, 40930, Finland
  • Investigational Site Number 246002
    Oulu, 90100, Finland
  • Investigational Site Number 246001
    Oulu, 90220, Finland
  • Investigational Site Number 246009
    Pori, 28100, Finland
  • Investigational Site Number 246004
    Rauma, 26100, Finland
  • Investigational Site Number 250008
    Amiens Cedex 1, 80054, France
  • Investigational Site Number 250011
    Bordeaux, 33000, France
  • Investigational Site Number 250009
    Caen, 14000, France
  • Investigational Site Number 250001
    Corbeil Essonnes, 91100, France
  • Investigational Site Number 250005
    Eaubonne, France
  • Investigational Site Number 250026
    La Rochelle Cedex 1, 17019, France
  • Investigational Site Number 250020
    Montpellier, 34059, France
  • Investigational Site Number 250015
    Mulhouse, France
  • Investigational Site Number 250003
    Paris, 75018, France
  • Investigational Site Number 250010
    Pierre-Bénite, 69310, France
  • Investigational Site Number 250014
    Pierre-Bénite, 69310, France
  • Investigational Site Number 250025
    POITIERS Cedex, 86021, France
  • Investigational Site Number 250002
    Valenciennes, 59322, France
  • Investigational Site Number 250013
    Vandoeuvre Les Nancy Cedex, 54511, France
  • Investigational Site Number 300002
    Athens, 18454, Greece
  • Investigational Site Number 300003
    Kalamata, Greece
  • Investigational Site Number 300001
    Lamia, 35100, Greece
  • Investigational Site Number 300004
    Thessaloniki, 56429, Greece
  • Investigational Site Number 372003
    Dublin 4, Ireland
  • Investigational Site Number 372002
    Dublin 7, Ireland
  • Investigational Site Number 380033
    Arzignano (VI), 36071, Italy
  • Investigational Site Number 380016
    Catania, 95122, Italy
  • Investigational Site Number 380004
    Catania, Italy
  • Investigational Site Number 380006
    Catanzaro, Italy
  • Investigational Site Number 380031
    Eboli, 84025, Italy
  • Investigational Site Number 380007
    Forlì, Italy
  • Investigational Site Number 380018
    Genova, 16132, Italy
  • Investigational Site Number 380020
    Iglesias (CI), 09016, Italy
  • Investigational Site Number 380015
    Milano, 20132, Italy
  • Investigational Site Number 380001
    Milano, 20162, Italy
  • Investigational Site Number 380012
    Milano, Italy
  • Investigational Site Number 380011
    Orbassano (TO), 10043, Italy
  • Investigational Site Number 380026
    Padova, Italy
  • Investigational Site Number 380021
    Palermo, 90127, Italy
  • Investigational Site Number 380014
    Partinico, 90047, Italy
  • Investigational Site Number 380032
    Roma, 00133, Italy
  • Investigational Site Number 380002
    Roma, 00161, Italy
  • Investigational Site Number 380023
    Roma, Italy
  • Investigational Site Number 380036
    San Benedetto del Tronto, 63074, Italy
  • Investigational Site Number 380024
    Sarzana, Italy
  • Investigational Site Number 380013
    Savigliano (CN), 12038, Italy
  • Investigational Site Number 380017
    Sesto S. Giovanni, 20099, Italy
  • Investigational Site Number 380025
    Torino, 10128, Italy
  • Investigational Site Number 642008
    Arad, Romania
  • Investigational Site Number 642005
    Baia MAre, Romania
  • Investigational Site Number 642002
    Brasov, 500326, Romania
  • Investigational Site Number 642006
    Brasov, 500326, Romania
  • Investigational Site Number 642003
    Cluj-Napoca, 400006, Romania
  • Investigational Site Number 642007
    Cluj-Napoca, 400006, Romania
  • Investigational Site Number 642004
    Targu-Mures, 540015, Romania
  • Investigational Site Number 642001
    Timisoara, 300125, Romania
  • Investigational Site Number 724002
    Barcelona, 08003, Spain
  • Investigational Site Number 724019
    Barcelona, 08035, Spain
  • Investigational Site Number 724012
    Barcelona, 08036, Spain
  • Investigational Site Number 724011
    Barcelona, Spain
  • Investigational Site Number 724027
    Castellón, 12004, Spain
  • Investigational Site Number 724028
    Córdoba, 14004, Spain
  • Investigational Site Number 724008
    Galdakao (Bilbao), 48960, Spain
  • Investigational Site Number 724010
    León, 24071, Spain
  • Investigational Site Number 724001
    LLeida, Spain
  • Investigational Site Number 724013
    Madrid, 28007, Spain
  • Investigational Site Number 724018
    Madrid, Spain
  • Investigational Site Number 724020
    Málaga, 29010, Spain
  • Investigational Site Number 724025
    Móstoles, 28933, Spain
  • Investigational Site Number 724006
    Palma de Mallorca, 07010, Spain
  • Investigational Site Number 724007
    Palma de Mallorca, 07010, Spain
  • Investigational Site Number 724024
    Pontevedra, 36071, Spain
  • Investigational Site Number 724017
    Sabadell, 08208, Spain
  • Investigational Site Number 724022
    San Cristóbal De La Laguna - Santa Cruz De Tenerife, 38320, Spain
  • Investigational Site Number 724003
    San Juan de Alicante, 3550, Spain
  • Investigational Site Number 724030
    Sant Joan Despí, 08970, Spain
  • Investigational Site Number 724023
    Santa Cruz de Tenerife, 38010, Spain
  • Investigational Site Number 724014
    Santiago de Compostela, 15706, Spain
  • Investigational Site Number 724005
    Sevilla, 41003, Spain
  • Investigational Site Number 724016
    Sevilla, 41010, Spain
  • Investigational Site Number 724004
    Sevilla, 41071, Spain
  • Investigational Site Number 724021
    Valencia, 46010, Spain
  • Investigational Site Number 724009
    Valladolid, 47011, Spain
  • Investigational Site Number 724029
    Vigo, 36200, Spain
  • Investigational Site Number 756003
    Bern, 3010, Switzerland
  • Investigational Site Number 756002
    St. Gallen, 9007, Switzerland
  • Investigational Site Number 826033
    Atherstone, CV91EU, United Kingdom
  • Investigational Site Number 826016
    Ayr, KA66DX, United Kingdom
  • Investigational Site Number 826039
    Blackburn, BB21AX, United Kingdom
  • Investigational Site Number 826008
    Bradford on Avon, BA151DQ, United Kingdom

Showing the first 100 of 118 sites across 10 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Semlitsch T, Engler J, Siebenhofer A, Jeitler K, Berghold A, Horvath K. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2020 Nov 9;11(11):CD005613. doi: 10.1002/14651858.CD005613.pub4. PubMed 33166419 ↗
  • Freemantle N, Mauricio D, Giaccari A, Bailey T, Roussel R, Franco D, Berthou B, Pilorget V, Westerbacka J, Bosnyak Z, Bonnemaire M, Cali AMG, Nguyen-Pascal ML, Penfornis A, Perez-Maraver M, Seufert J, Sullivan SD, Wilding J, Wysham C, Davies M. Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus. Curr Med Res Opin. 2020 Apr;36(4):571-581. doi: 10.1080/03007995.2019.1708287. Epub 2020 Jan 19. PubMed 31865758 ↗

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2015, a primary completion of Oct 2017 and a completion of Oct 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2016
First posted
Nov 18, 2016
Start
Dec 21, 2015
Primary completionActual
Oct 20, 2017
CompletionActual
Oct 20, 2017
Last update
Apr 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02967211
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Nov 18, 2016
Start date
Dec 21, 2015
Primary completion
Oct 20, 2017
Completion
Oct 20, 2017
Last update
Apr 25, 2022

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Glargine

Start the discussion